← Leaderboards
Howard S Hochster
New York University School Of Medicine
$9,390,994
Attributed
$9,758,661
Total exposure
49
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,758,661 · 49
By mechanism
P30$5,568,216 · 3
R01$1,766,451 · 1
U10$1,704,401 · 1
M01$719,593 · 44
Top collaborators
- Peter M Glazer1 shared
- Thomas Rutherford1 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyDrug Screening /EvaluationCombination ChemotherapyClinical TrialsCombination Cancer TherapyGrantMalignant NeoplasmsCis Platinum CompoundClinical Trial Phase IProtocols DocumentationResearch PersonnelCaringEnsureBaseAntineoplasticsUniversitiesLeadershipYale Cancer CenterTopotecanPaclitaxelResponse
Grant awards (138)
Clinical Protocol and Data Management$799,481
P30 · FY2022 · CA · contact PI
Protocol Review and Monitoring System$240,914
P30 · FY2022 · CA · contact PI
Clinical Protocol and Data Management$799,481
P30 · FY2021 · CA · contact PI
Protocol Review and Monitoring System$240,914
P30 · FY2021 · CA · contact PI
Clinical Protocol and Data Management$799,481
P30 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$240,914
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$799,481
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$240,914
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$11,904
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$11,904
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$799,481
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$240,914
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$11,904
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$11,904
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$11,904
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$11,904
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$2,856
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,856
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,682
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$2,682
P30 · FY2018 · CA · contact PI
Yale Cancer Center NCTN$49,901
U10 · FY2017 · CA · contact PI
Yale Cancer Center NCTN$551,500
U10 · FY2016 · CA · contact PI
Yale Cancer Center NCTN$551,500
U10 · FY2015 · CA · contact PI
Yale Cancer Center NCTN$551,500
U10 · FY2014 · CA · contact PI
Clinical Trials Office$180,896
P30 · FY2009 · CA · contact PI
Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA$421,996
R01 · FY2008 · CA · contact PI
Clinical Trials Office$102,845
P30 · FY2008 · CA · contact PI
CLINICAL TRIAL: CETUXIMAB PLUS CAPECITABINE AND OXALIPLATIN FOR METASTATIC COLOR$7,718
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ECOG N0147: OXAL PLUS 5-FU/CF W/WO CETUXIMAB IN STAGE III COLON$5,145
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ECOG E5204: COMPARING TWO POSTOPERATIVE REGIMENS FOR RECTAL CANC$1,896
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCE$948
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ECOG E5202: COMPARING TWO REGIMENS IN PATIENTS WITH STAGE II COL$271
M01 · FY2008 · RR · contact PI
Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA$413,822
R01 · FY2007 · CA · contact PI
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER$23,277
M01 · FY2007 · RR · contact PI
OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY$9,862
M01 · FY2007 · RR · contact PI
ECOG N0147: OXAL PLUS 5-FU/CF W/WO CETUXIMAB IN STAGE III COLON CANCERECOG N0$9,468
M01 · FY2007 · RR · contact PI
Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA$499,767
R01 · FY2006 · CA · contact PI
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER$75,754
M01 · FY2006 · RR · contact PI
OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY$29,460
M01 · FY2006 · RR · contact PI
CETUXIMAB PLUS CAPECITABINE AND OXALIPLATIN FOR METASTATIC COLORECTAL CANCER$23,381
M01 · FY2006 · RR · contact PI
BEVACIZUMAB/CETUXIMAB/IRINOTECAN OR BEVACIZUMAB/CETUXIMAB IN COLORECTAL CANCER$22,446
M01 · FY2006 · RR · contact PI
Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA$430,866
R01 · FY2005 · CA
OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY$31,512
M01 · FY2005 · RR
N9831: DOXORUBICIN/CYCLOPHOSPHAMIDE/TAXOL +OR -TRASTUZUMAB FOR BREAST CANCER$26,259
M01 · FY2005 · RR
ECOG E3201: PHASE III STUDY IN PATIENTS WITH STAGE II OR III RECTAL CANCER$16,711
M01 · FY2005 · RR
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER$16,711
M01 · FY2005 · RR
BEVACIZUMAB/CETUXIMAB/IRINOTECAN OR BEVACIZUMAB/CETUXIMAB IN COLORECTAL CANCER$4,774
M01 · FY2005 · RR
THE FARNESYL TRANSFERASE INHIBITOR R115777 IN COMBINATION WITH TOPOTECAN$2,388
M01 · FY2005 · RR
ECOG E6201: GEMCITABINE AND OXALIPLATIN VERSUS GEMCITABINE IN PANCREATIC CANCER$477
M01 · FY2005 · RR
Gemcitabine &Cisplatin Followed By Chemo-RT+/- Surgery for Pancreatic Cancer$16,259
M01 · FY2004 · RR
Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX4) in Advanced Colorectal Cancer$10,162
M01 · FY2004 · RR
The Farnesyl Transferase Inhibitor R115777 in Combination with Topotecan$3,049
M01 · FY2004 · RR
N9831: Doxorubicin/Cyclophosphamide/Taxol +or -Trastuzumab for Breast Cancer$2,033
M01 · FY2004 · RR
Oxaliplatin (Eloxatin) with Bortezomib in Patients with Advanced Malignancy$1,524
M01 · FY2004 · RR
21 DAY TOPOTECAN INFUSION WITH CISPLATIN IN OVARIAN CANCER$0
M01 · FY2002 · RR
NAVELBINE AND CISPLATIN IN PATIENTS WITH ADVANCED BREAST CANCER$0
M01 · FY2002 · RR
5 FU PLUS LEVAMISOLE PLUS PANOREX MONOCLONAL ANTIBODY IN DUKE'S C COLON CANCER$0
M01 · FY2002 · RR
CORRELATION OF THYMIDYLATE SYNTHASE IN 5-FU TREATED COLORECTAL CANCER$0
M01 · FY2002 · RR
THYMITAQ VERSUS METHOTREXATE IN ADVANCED HEAD AND NECK CANCER$0
M01 · FY2002 · RR
RANDOMIZED PHASE III TRIAL IN METASTATIC NONSMALL CELL LUNG CANCER$0
M01 · FY2002 · RR
28 DAY REGIMEN OF ORAL 5-FU PLUS 776C85 IN UNTREATED COLORECTAL CANCER$0
M01 · FY2002 · RR
CISPLATIN PLUS PACLITAXEL IN ADVANCED CARCINOMA OF THE UROTHELIUM$0
M01 · FY2002 · RR
PROLONGED LOW DOSE TOPOTECAN INFUSION COMBINED W/ CHEST IRRADIATION$0
M01 · FY2002 · RR
GEMCITABINE &CISPLATIN FOLLOWED BY RADIATION &SURGERY FOR PANCREATIC CANCER$0
M01 · FY2002 · RR
FUMA 3008: 28 DAYS ORAL 5FU + 776C85 VERSUS IV 5FU + LEUKOVORIN IN COLON CANCER$0
M01 · FY2002 · RR
ECOGC9741: ATC VS ACT AT 14 OR 21 DAYS NODE + STAGE II &IIIA BREAST NEOPLASM$0
M01 · FY2002 · RR
LOW DOSE CONTINUOUS TOPOTECAN + DOXIL FOR ADVANCED MALIGNANCIES$0
M01 · FY2002 · RR
CONTINUOUS INFUSION OF TOPOTECAN + 5 FU &LEUCOVORIN IN ADVANCED MALIGNANCIES$0
M01 · FY2002 · RR
ECOG 9581: ADJUVANT MOAB17 1A VS NO ADJUVANT FOR STAGE II COLON CANCER$0
M01 · FY2002 · RR
CPT 11 &CISPLATIN IN ADVANCED GASTRIC CARCINOMA$0
M01 · FY2002 · RR
ECOG 2297: GEMCITABINE &5FU VS GEMCITABINE IN PANCREATIC CANCER$0
M01 · FY2002 · RR
ECOG E2197: ADRIAMYCIN &TAXOTERE VERSUS ADRIAMYCIN &CYTOXAN FOR BREAST CANCER$0
M01 · FY2002 · RR
NAVELBINE AND CISPLATIN IN PATIENTS WITH ADVANCED BREAST CANCER$0
M01 · FY2001 · RR
LOW DOSE CONTINUOUS TOPOTECAN + DOXIL FOR ADVANCED MALIGNANCIES$0
M01 · FY2001 · RR
ECOGC9741: ATC VS ACT AT 14 OR 21 DAYS NODE + STAGE II &IIIA BREAST NEOPLASM$0
M01 · FY2001 · RR
FUMA 3008: 28 DAYS ORAL 5FU + 776C85 VERSUS IV 5FU + LEUKOVORIN IN COLON CANCER$0
M01 · FY2001 · RR
GEMCITABINE &CISPLATIN FOLLOWED BY RADIATION &SURGERY FOR PANCREATIC CANCER$0
M01 · FY2001 · RR
PROLONGED LOW DOSE TOPOTECAN INFUSION COMBINED W/ CHEST IRRADIATION$0
M01 · FY2001 · RR
CISPLATIN PLUS PACLITAXEL IN ADVANCED CARCINOMA OF THE UROTHELIUM$0
M01 · FY2001 · RR
ECOG E2197: ADRIAMYCIN &TAXOTERE VERSUS ADRIAMYCIN &CYTOXAN FOR BREAST CANCER$0
M01 · FY2001 · RR
ECOG 9581: ADJUVANT MOAB17 1A VS NO ADJUVANT FOR STAGE II COLON CANCER$0
M01 · FY2001 · RR
ECOG 2297: GEMCITABINE &5FU VS GEMCITABINE IN PANCREATIC CANCER$0
M01 · FY2001 · RR
CONTINUOUS INFUSION OF TOPOTECAN + 5 FU &LEUCOVORIN IN ADVANCED MALIGNANCIES$0
M01 · FY2001 · RR
CPT 11 &CISPLATIN IN ADVANCED GASTRIC CARCINOMA$0
M01 · FY2001 · RR
28 DAY REGIMEN OF ORAL 5-FU PLUS 776C85 IN UNTREATED COLORECTAL CANCER$0
M01 · FY2001 · RR
RANDOMIZED PHASE III TRIAL IN METASTATIC NONSMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
THYMITAQ VERSUS METHOTREXATE IN ADVANCED HEAD AND NECK CANCER$0
M01 · FY2001 · RR
21 DAY TOPOTECAN INFUSION WITH CISPLATIN IN OVARIAN CANCER$0
M01 · FY2001 · RR
CORRELATION OF THYMIDYLATE SYNTHASE IN 5-FU TREATED COLORECTAL CANCER$0
M01 · FY2001 · RR
5 FU PLUS LEVAMISOLE PLUS PANOREX MONOCLONAL ANTIBODY IN DUKE'S C COLON CANCER$0
M01 · FY2001 · RR
LOW DOSE CONTINUOUS TOPOTECAN + DOXIL FOR ADVANCED MALIGNANCIES$21,006
M01 · FY2000 · RR
RANDOMIZED PHASE III TRIAL IN METASTATIC NONSMALL CELL LUNG CANCER$21,006
M01 · FY2000 · RR
THYMITAQ VERSUS METHOTREXATE IN ADVANCED HEAD AND NECK CANCER$21,006
M01 · FY2000 · RR
21 DAY TOPOTECAN INFUSION WITH CISPLATIN IN OVARIAN CANCER$21,006
M01 · FY2000 · RR
CORRELATION OF THYMIDYLATE SYNTHASE IN 5-FU TREATED COLORECTAL CANCER$21,006
M01 · FY2000 · RR
5 FU PLUS LEVAMISOLE PLUS PANOREX MONOCLONAL ANTIBODY IN DUKE'S C COLON CANCER$21,006
M01 · FY2000 · RR
NAVELBINE AND CISPLATIN IN PATIENTS WITH ADVANCED BREAST CANCER$21,006
M01 · FY2000 · RR
ECOG E2197: ADRIAMYCIN &TAXOTERE VERSUS ADRIAMYCIN &CYTOXAN FOR BREAST CANCER$21,006
M01 · FY2000 · RR
ECOG 2297: GEMCITABINE &5FU VS GEMCITABINE IN PANCREATIC CANCER$21,006
M01 · FY2000 · RR
CPT 11 &CISPLATIN IN ADVANCED GASTRIC CARCINOMA$21,006
M01 · FY2000 · RR
ECOG 9581: ADJUVANT MOAB17 1A VS NO ADJUVANT FOR STAGE II COLON CANCER$21,006
M01 · FY2000 · RR
CONTINUOUS INFUSION OF TOPOTECAN + 5 FU &LEUCOVORIN IN ADVANCED MALIGNANCIES$21,006
M01 · FY2000 · RR
28 DAY REGIMEN OF ORAL 5-FU PLUS 776C85 IN UNTREATED COLORECTAL CANCER$21,006
M01 · FY2000 · RR
ECOGC9741: ATC VS ACT AT 14 OR 21 DAYS NODE + STAGE II &IIIA BREAST NEOPLASM$21,006
M01 · FY2000 · RR
FUMA 3008: 28 DAYS ORAL 5FU + 776C85 VERSUS IV 5FU + LEUKOVORIN IN COLON CANCER$21,006
M01 · FY2000 · RR
GEMCITABINE &CISPLATIN FOLLOWED BY RADIATION &SURGERY FOR PANCREATIC CANCER$21,006
M01 · FY2000 · RR
PROLONGED LOW DOSE TOPOTECAN INFUSION COMBINED W/ CHEST IRRADIATION$21,006
M01 · FY2000 · RR
CISPLATIN PLUS PACLITAXEL IN ADVANCED CARCINOMA OF THE UROTHELIUM$21,006
M01 · FY2000 · RR
21 DAY TOPOTECAN INFUSION WITH CISPLATIN IN OVARIAN CANCER$0
M01 · FY2000 · RR
THYMITAQ VERSUS METHOTREXATE IN ADVANCED HEAD AND NECK CANCER$0
M01 · FY2000 · RR
ECOG 9581: ADJUVANT MOAB17 1A VS NO ADJUVANT FOR STAGE II COLON CANCER$0
M01 · FY2000 · RR
CONTINUOUS INFUSION OF TOPOTECAN + 5 FU &LEUCOVORIN IN ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
RANDOMIZED PHASE III TRIAL IN METASTATIC NONSMALL CELL LUNG CANCER$0
M01 · FY2000 · RR
28 DAY REGIMEN OF ORAL 5-FU PLUS 776C85 IN UNTREATED COLORECTAL CANCER$0
M01 · FY2000 · RR
LOW DOSE CONTINUOUS TOPOTECAN + DOXIL FOR ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
PROLONGED LOW DOSE TOPOTECAN INFUSION COMBINED W/ CHEST IRRADIATION$0
M01 · FY2000 · RR
ECOGC9741: ATC VS ACT AT 14 OR 21 DAYS NODE + STAGE II &IIIA BREAST NEOPLASM$0
M01 · FY2000 · RR
CISPLATIN PLUS PACLITAXEL IN ADVANCED CARCINOMA OF THE UROTHELIUM$0
M01 · FY2000 · RR
FUMA 3008: 28 DAYS ORAL 5FU + 776C85 VERSUS IV 5FU + LEUKOVORIN IN COLON CANCER$0
M01 · FY2000 · RR
GEMCITABINE &CISPLATIN FOLLOWED BY RADIATION &SURGERY FOR PANCREATIC CANCER$0
M01 · FY2000 · RR
NAVELBINE AND CISPLATIN IN PATIENTS WITH ADVANCED BREAST CANCER$0
M01 · FY2000 · RR
FIRST LINE THERAPY OF OVARIAN CANCER$0
M01 · FY2000 · RR
FIRST LINE THERAPY OF OVARIAN CANCER$0
M01 · FY2000 · RR
CARBOPLATIN WITH PROLONGED ORAL TOPOTECAN FOR CANCER$0
M01 · FY2000 · RR
CARBOPLATIN WITH PROLONGED ORAL TOPOTECAN FOR CANCER$0
M01 · FY2000 · RR
CARBOPLATIN, PACLITAXEL, AND HERCEPTIN IN NSCLC$0
M01 · FY2000 · RR
CARBOPLATIN, PACLITAXEL, AND HERCEPTIN IN NSCLC$0
M01 · FY2000 · RR
RFS 2000 ( 9 NITROCAMPTOTHECIN) IN PANCREAS CANCER$0
M01 · FY2000 · RR
RFS 2000 ( 9 NITROCAMPTOTHECIN) IN PANCREAS CANCER$0
M01 · FY2000 · RR
OXALIPLATIN FOR PREVIOUSLY TREATED COLORECTAL CANCER$0
M01 · FY2000 · RR
OXALIPLATIN FOR PREVIOUSLY TREATED COLORECTAL CANCER$0
M01 · FY2000 · RR
PROLONGED LOW DOSE TOPOTECAN INFUSION WITH TAXOL$0
M01 · FY2000 · RR
PROLONGED LOW DOSE TOPOTECAN INFUSION WITH TAXOL$0
M01 · FY2000 · RR
5 FU PLUS LEVAMISOLE PLUS PANOREX MONOCLONAL ANTIBODY IN DUKE'S C COLON CANCER$0
M01 · FY2000 · RR
ECOG E2197: ADRIAMYCIN &TAXOTERE VERSUS ADRIAMYCIN &CYTOXAN FOR BREAST CANCER$0
M01 · FY2000 · RR
CORRELATION OF THYMIDYLATE SYNTHASE IN 5-FU TREATED COLORECTAL CANCER$0
M01 · FY2000 · RR
ECOG 2297: GEMCITABINE &5FU VS GEMCITABINE IN PANCREATIC CANCER$0
M01 · FY2000 · RR
CPT 11 &CISPLATIN IN ADVANCED GASTRIC CARCINOMA$0
M01 · FY2000 · RR